Skip to main content
. 2021 Jun 10;9(6):665. doi: 10.3390/biomedicines9060665

Figure 1.

Figure 1

Modes of Action of ARGX-111. ARGX-111 combines 4 distinct mechanisms of action: (1) it potently competes with HGF for MET binding, thus inhibiting ligand-dependent MET activity; (2) it induces receptor down-regulation, thus curbing HGF-independent MET activity; (3) it engages NK cells to kill MET-expressing cancer cells, thus displaying MET-specific cytotoxic activity; and (4) it has increased tumor targeting and penetration through interaction with FcRn.